Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Neuropsychiatric side effects of semaglutide in patients with dementia.

Jamshed N, Rehman ST, Khan N

BMJ case reports4 Aug 2025

PMID40759509 (opens in a new tab)DOI10.1136/bcr-2024-262743 (opens in a new tab)PepBankPUB-40759509
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In an older woman with dementia and type 2 diabetes, severe psychological symptoms including apathy developed after starting semaglutide and improved after it was stopped.

    In plain wordsIn one older woman with dementia and diabetes, apathy and other symptoms appeared after starting semaglutide and improved once it was stopped.

    Peptide
    Semaglutide
    Outcome
    IncreaseApathy and psychological symptoms
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and decreased appetite.
    1 context sentence
    Summary · context
    These symptoms markedly improved after the medication was discontinued.
  2. 02HumanCase report or seriesSafety outcome

    In an older woman with dementia and type 2 diabetes, significant weight loss developed after starting semaglutide and improved after it was stopped.

    In plain wordsIn one older woman with dementia and diabetes, significant weight loss followed the start of semaglutide and improved once it was stopped.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and decreased appetite.
    1 context sentence
    Summary · context
    These symptoms markedly improved after the medication was discontinued.
  3. 03HumanCase report or seriesSafety outcome

    In an older woman with dementia and type 2 diabetes, appetite decreased after starting semaglutide and improved after it was stopped.

    In plain wordsIn one older woman with dementia and diabetes, appetite fell after starting semaglutide and improved once it was stopped.

    Peptide
    Semaglutide
    Outcome
    DecreaseAppetite
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and decreased appetite.
    1 context sentence
    Summary · context
    These symptoms markedly improved after the medication was discontinued.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.